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Abstract
Background: Nitric oxide (NO) is an inflammatory mediator, which acts as a cytotoxic agent and
modulates immune responses and inflammation. p38 mitogen-activated protein kinase (MAPK)
signal transduction pathway is    activated by chemical and physical stress and regulates immune
responses. Previous studies have shown that p38 MAPK pathway regulates NO production induced
by inflammatory stimuli. The aim of the present study was to investigate the mechanisms involved
in the regulation of inducible NO synthesis by p38 MAPK pathway.
Results: p38 MAPK inhibitors SB203580 and SB220025 stimulated lipopolysaccharide (LPS)-
induced inducible nitric oxide synthase (iNOS) expression and NO production in J774.2 murine
macrophages. Increased iNOS mRNA expression was associated with reduced degradation of
iNOS mRNA. Treatment with SB220025 increased also LPS-induced c-Jun N-terminal kinase (JNK)
activity. Interestingly, JNK inhibitor SP600125 reversed the effect of SB220025 on LPS-induced
iNOS mRNA expression and NO production.
Conclusion: The results suggest that inhibition of p38 MAPK by SB220025 results in increased
JNK activity, which leads to stabilisation of iNOS mRNA, to enhanced iNOS expression and to
increased NO production.
Background
Nitric oxide (NO) is a highly reactive signaling molecule
and inflammatory mediator, which acts as a cytotoxic
agent and modulates immune responses and inflamma-
tion [1,2]. High amounts of NO are produced for pro-
longed times by inducible nitric oxide synthase (iNOS) in
response to proinflammatory cytokines and bacterial
products [3,4]. iNOS expression is regulated both at tran-
scriptional and posttranscriptional level. Several tran-
scription factors which regulate iNOS promoter activity
have been characterized, but the mechanisms and factors
regulating iNOS mRNA stability are largely unknown
[2,5].
Mitogen-activated protein kinases (MAPKs) are a family
of serine/threonine kinases that are part of the signal
transduction pathways, which connect inflammatory and
various other extracellular signals to intracellular
responses e.g. gene expression [6]. p38 MAPK and c-Jun
N-terminal kinase (JNK) are members of the MAPK fam-
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p38 and JNK regulate immune responses and expression
of various cytokines e.g. tumor necrosis factor-α, inter-
leukin-1 and interleukin-6 [7].
JNK and p38 MAPK are also involved in regulation of
iNOS expression. Previous studies have shown that JNK
pathway belongs to the factors that mediate the up-regu-
lation of iNOS expression [8-10]. Depending on the cell-
type and stimulation used, p38 MAPK has been reported
to have either up-regulatory role [11-13], down-regulatory
role [14-16] or no role [17,18] in iNOS expression. We
have previously reported that p38 MAPK inhibitors
enhance iNOS expression and NO production in LPS-
stimulated J774 macrophages [19]. The detailed mecha-
nism behind those stimulatory effects is not known.
The aim of the present study was to investigate the mech-
anism by which p38 inhibition leads to increase in NO
production. The results suggest that inhibition of p38
MAPK increases LPS-induced JNK activity, which leads to
stabilisation of iNOS mRNA and increased production of
NO in activated macrophages.
Results
p38 MAPK inhibitor SB220025 increases LPS-induced NO 
production and iNOS expression
We have previously shown that pyridinyl imidazole
inhibitor of p38 MAPK SB203580 [20] stimulates LPS-
induced NO production [19]. SB220025 is a recently
developed potent and specific inhibitor of p38 MAPK
with an IC50 value of 60 nM in kinase activity assay [21].
Figure 1A shows that SB220025 had a concentration
dependent stimulatory effect on LPS-induced NO produc-
tion and maximal effect (50%) was achieved at drug con-
centration of 0,5 µM. The effect of SB220025 was similar
to the effect of SB203580 (1 µM) (Fig. 1B). A structurally
related control compound SB202474, which does not
inhibit p38 MAPK [22], had no effect on NO production.
The stimulatory effect of SB220025 was maximal when
the compound was added to cells 1 h after LPS (Fig 2A).
This result is in line with our previous report in which we
showed that the stimulatory effect of SB203580 was max-
imal when the compound was added 1 h after LPS [19].
The levels of activated p38 peaked in 30 min after LPS,
were still high at 1 h and declined gradually thereafter so
that activated p38 could be detected even 4 h after LPS
(Fig. 2B). Thus, the stimulation of LPS-induced iNOS pro-
duction by SB220025 could result from inhibition of p38,
even when the compound was added to cells 1–2 h after
LPS. SB220025 had a clear stimulatory effect also on iNOS
protein expression, whereas the negative control com-
pound SB202747 had no effect (Fig. 3A). Interestingly,
SB220025 did not increase LPS-induced iNOS mRNA lev-
els when measured 4 h after addition of LPS, whereas a
Effect of p38 MAPK inhibitor SB220025 on LPS-induced NO productionFigure 1
Effect of p38 MAPK inhibitor SB220025 on LPS-
induced NO production. (A) Cells were stimulated with 
LPS (10 ng/ml) and treated with various concentrations of 
SB220025 1 h after LPS stimulation. After 24 h incubation the 
nitrite concentrations were measured as a marker of NO 
production. Values are mean ± S.E.M. (n = 6). (B) Cells were 
stimulated with LPS 1 h before addition of tested com-
pounds. 24 h after addition of LPS the nitrite concentrations 
were measured as marker of NO production. Values are 
mean ± S.E.M. (n = 6). ***P < 0.001 compared with cells 
treated with LPS only.Page 2 of 12
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measured 10 h after addition of LPS (Fig. 3B).
SB220025 stabilises iNOS mRNA
Because SB220025 had no effect on iNOS mRNA levels
when measured 4 h after LPS, but significantly increased
the mRNA levels when measured 10 h after LPS, we
hypothesized that SB220025 might stabilize iNOS
mRNA.
To study the effect of SB220025 on the stability of iNOS
mRNA, the cells were treated with LPS or LPS+SB220025
and cells were incubated for 6 h. Thereafter total RNA was
isolated at 2 h intervals. The iNOS mRNA levels in cells
were reducing rapidly between 6–12 h after LPS stimula-
tion. The amount of iNOS mRNA in LPS treated cells
halved in about 3 h (Fig. 4). The reduction in the amount
of iNOS mRNA was slower in cells treated with
LPS+SB220025 (iNOS mRNA halved in about 4,5 h).
Actinomycin D (an inhibitor of transcription) was added
to cells 6 h after LPS in an attempt to test whether the
slowed disappearance of iNOS mRNA in cells treated with
LPS+SB220025 was due to increased rate of transcription
of iNOS gene or reduced degradation of mRNA. Interest-
ingly, the level of mRNA was reducing at the same or
slower rate in cells treated with LPS+actinomycin D com-
pared with cells treated with LPS only, suggesting that no
significant transcription of iNOS gene occurs in cells 6 –
12 h after LPS stimulation and that actinomycin D itself
inhibits the degradation of iNOS mRNA. Thus, the slowed
disappearance of iNOS mRNA in cells treated with
SB220025 was most likely due to reduced degradation of
mRNA.
p38α and p38β expression in J774 macrophages
There are four known isoforms of p38 MAPK (α, β, γ and
δ) [6], and SB203580 has been shown to inhibit p38α and
p38β but not p38γ and p38δ isoforms [23]. p38α and
p38β have been recently reported to differently regulate
iNOS expression [24]. Therefore we wanted to investigate
whether J774.2 macrophages express p38α and p38β
isoenzymes.
We used real-time RT-PCR to study the p38α and p38β
mRNA expression in J774.2 macrophages. Both unstimu-
lated and LPS stimulated cells expressed p38α mRNA at
relatively high level as compared to GAPDH mRNA (Fig.
5A). In contrast, only low level expression of p38β mRNA
was detected. In line with the mRNA result, Western blot
showed p38α protein expression (Fig. 5B), whereas no
p38β protein could be detected by Western blotting.
SB220025 increases LPS-induced JNK activity
Opposite roles for p38 MAPK and JNK have recently been
reported on thrombin induced iNOS expression in
RAW264.7 macrophages [25]. JNK and p38 MAPK have
common target proteins and there is crosstalk between
these signaling cascades [26]. Furthermore, we have previ-
ously reported that JNK inhibition destabilizes iNOS
mRNA [10]. Therefore we hypothesized that the roles of
JNK and p38 MAPK pathways on LPS-induced iNOS
The effect of SB220025 on NO production when added before or at various time points after LPS (A) and tim  cours  f p38 MAPK activation following LPS (B)Figure 2
The effect of SB220025 on NO production when 
added before or at various time points after LPS (A) 
and time course of p38 MAPK activation following 
LPS (B). (A) Cells were treated with SB220025 1 h before 
or at indicated time points after stimulation with LPS. After 
24 h incubation, the nitrite concentrations were measured as 
a marker of NO production. Values are mean ± S.E.M. (n = 
6). **P < 0.01, ***P < 0.001 compared with cells treated with 
LPS only. (B) Cells were stimulated with LPS (10 ng/ml) and 
incubations were terminated at indicated time points. Parallel 
immunoblots were run from same cell lysates using antibod-
ies against phosphorylated p38 (pp38) and total p38. The 
result is representative of three experiments with similar 
results.Page 3 of 12
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ing whether inhibition of p38 MAPK modulates the activ-
ity of JNK.
LPS induced a rapid phosphorylation of JNK. The phos-
phorylation peaked at 0.5 h and declined rapidly thereaf-
ter, remaining <33% of the maximum when measured 2–
8 h after LPS (Fig. 6). SB220025, when given 1 h after LPS,
further increased the LPS-induced JNK phosphorylation
compared with cells treated with LPS only. In SB220025-
treated cells the amount of phosphorylated JNK remained
>55% of the maximum level up to 4 h and declined there-
after. SB220025 alone did not activate JNK (Fig. 7).
JNK phosphorylates c-Jun at residues Ser63 and Ser73
[27]. In parallel to increased phosphorylation of JNK by
SB220025, increased phosphorylation of c-Jun at Ser63
was observed (Fig. 8A). Similar results were obtained
when phosphorylation of Ser73 was measured (data not
shown). This suggests that the increased phosphorylation
Effect of p38 MAPK inhibitor SB220025 on LPS-induced iNOS ex ressionFigur  3
Effect of p38 MAPK inhibitor SB220025 on LPS-
induced iNOS expression. (A) Cells were stimulated with 
LPS 1 h before addition of SB220025. After 24 h, incubations 
were terminated and immunoblots were run using antibody 
against iNOS and actin. The result is representative of three 
experiments with similar results. (B) Cells were stimulated 
with LPS 1 h before addition of SB220025. Incubations were 
terminated at indicated time points and extracted total RNA 
was subjected to real time RT-PCR. iNOS mRNA levels 
were normalised against GAPDH. Values are mean ± S.E.M. 
(n = 3). *P < 0.05, ***P < 0.001 compared with cells treated 
with LPS only.
Effect of SB220025 on iNOS mRNA degradationFigure 4
Effect of SB220025 on iNOS mRNA degradation. 
Cells were stimulated with LPS (10 ng/ml) 1 h before addi-
tion of SB220025 (0,5 µM). Actinomycin D (actD) (0,5 µg/ml) 
was added to cells 6 h after LPS. Incubations were termi-
nated at the indicated time points after LPS and total RNA 
was isolated. iNOS and GAPDH mRNA was measured by 
real time RT-PCR. iNOS mRNA levels were normalized 
against GAPDH. Values are mean ± S.E.M. (n = 3).Page 4 of 12
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activity of JNK.
To rule out the possibility, that increased c-Jun phospho-
rylation was a result of reduced dephosphorylation, we
tested whether the effect of SB220025 could be reversed
with JNK inhibitor SP600125. Treatment with LPS and
SB220025 induced a 6 fold increase in c-Jun Ser63 phos-
phorylation compared with cells treated with LPS only
(Fig. 8B). In contrast, the negative control compound
SB202474 had no effect on c-Jun phosphorylation. The
SB220025-stimulated increase in c-Jun phosphorylation
was almost completely reversed by SP600125, suggesting
that the increase in c-Jun phosphorylation was due to
increased JNK activity and not due to reduced dephospho-
rylation.
The stimulatory effect of SB220025 on LPS-induced NO 
production and iNOS mRNA expression can be reversed by 
SP600125
To continue, we hypothesized that the stimulatory effect
of SB220025 on LPS-induced NO production was due to
increased JNK activity and therefore we tested the effect of
JNK inhibitor SP600125 on SB220025-stimulated NO
production.
SB220025 induced a clear increase in LPS-stimulated NO
production, whereas SP600125 inhibited NO production
(Fig. 9A). However, when cells were treated with a combi-
nation of SB220025 and SP600125 the level of NO pro-
duction was comparable to levels produced by cells
treated with LPS+SP600126. Thus, the effect of SB220025
was reversed by SP600125.
The same result was observed at the level of iNOS mRNA
expression. SB220025 increased the amounts of iNOS
mRNA to almost two fold compared with cells treated
with LPS only, whereas the negative control compound
SB202474 had no effect (Fig. 9B). SP600125 alone
reduced the LPS-stimulated iNOS mRNA levels slightly. In
addition, in the presence of the JNK inhibitor SP600125,
SB220025 had no stimulatory effect on iNOS mRNA lev-
els.
Cycloheximide increases JNK activity and iNOS mRNA 
expression
Cycloheximide is widely used as an inhibitor of protein
synthesis. However, cycloheximide also activates JNK
[28]. Therefore we continued by investigating whether
cycloheximide has similar effect on iNOS mRNA expres-
sion as SB220025. Cycloheximide at 0,05–0,1 µg/ml con-
centrations increased LPS-induced JNK activity (Fig. 10A).
Interestingly, cycloheximide had no significant effect on
iNOS mRNA expression when measured 4 h after LPS, but
increased iNOS mRNA levels >4 fold when measured 10
h after LPS (Fig. 10B). Furthermore, the effect of cyclohex-
imide on iNOS mRNA expression was partially inhibited
by SP600125 (Fig. 10C). These results show that the effect
of cycloheximide on JNK activity and iNOS expression
were very similar to the effect of SB220025.
Discussion
In the present study we have shown that inhibition of p38
MAPK by SB220025 increases LPS-induced JNK activity,
which leads to stabilization of iNOS mRNA and increased
iNOS expression and NO production in J774.2 macro-
phages.
Inhibitors of p38 MAPK have been shown to up-regulate
iNOS expression in IL-1β-stimulated rat mesangial cells
[14,24], in LPS+IFN-γ-stimulated RAW264.7γ macro-
phages [15], in interferon-γ (IFN-γ)+mannose-capped
lipoarabinomannan-stimulated RAW264.7γ macro-
phages [16] and in LPS-stimulated J774.A1 macrophages
[19]. In this study, a novel p38 MAPK inhibitor SB220025
increased LPS-induced NO production with an EC50 of
~100 nM, which is close to its IC50 value of p38 MAPK
inhibition (~60 nM) [21]. Furthermore, a structurally
related inactive control compound SB202474 had no
effect. These results together suggest that the observed
increase in NO production and iNOS expression was due
to inhibition of p38 MAPK. SB203580 inhibits the p38α
and p38β isoforms at equipotent efficiency, but does not
inhibit p38γ or p38δ [23]. To our knowledge there is no
published data about the isoform specificity of SB220025.
In the present study both SB203580 and SB220025 had
similar effect on LPS-induced NO production, thus it is
likely that the observed effects are mediated by p38α and/
or p38β. J774 macrophages were found to express p38α
mRNA and p38α protein at relatively high levels whereas
only low amounts of p38β mRNA were detected. Similar
pattern of p38α and p38β expression was reported by Lui
et al. (2004) in rat renal mesangial cells, in which p38
MAPK inhibition was also found to increase iNOS expres-
sion. In their further transfection experiments, Lui et al.
(2004) found that p38α mutant and p38β wild-type iso-
forms inhibited IL-1-induced iNOS expression suggesting
that the two isoforms have reciprocal effects on iNOS
expression in renal mesangial cells. Our results show that
inhibition of p38 enhances iNOS expression and NO pro-
duction in macrophages activated by LPS but further stud-
ies are required to clarify the roles of different p38 MAPK
isoforms in that process.
The mechanisms how p38 MAPK inhibitors enhance
iNOS expression and NO production have been unclear.
The present data suggest that inhibition of p38 enhances
JNK activity that results in stabilization of iNOS mRNA
and enhanced iNOS protein expression. Our results are in
line with those of Avdi et al. (2002) in which inhibitionPage 5 of 12
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in human neutrophils [29]. The inhibition of p38 MAPK
was found to reduce the activity of protein phosphatase-
2A which resulted in reduced dephosphorylation and
increased activity of JNK. Various protein phosphatases
are able to dephosphorylate MAPKs and are thus impor-
tant regulators of MAPK activity [30]. It is possible that
p38 MAPK regulates the activity of protein phosphatase-
Expression of p38α and p38β in J774Figure 5
Expression of p38α and p38β in J774.2 macrophages. (A) Real time RT-PCR analysis of the p38α, p38β and GAPDH 
mRNA expression in J774.2 macrophages. Shown is the relationship between the PCR cycle number and the ∆Rn which is the 
normalized reporter signal minus the background noise determined during the PCR cycles. Cells were treated with LPS (10 ng/
ml) or vehicle only. Total RNA was isolated after 8 h incubation. Six separate mRNA samples were analysed. (B) Cells were 
stimulated with LPS. After 24 h, incubations were terminated and immunoblots were run using antibody against p38α. The 
result is representative of three experiments with similar results.Page 6 of 12
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p38 MAPK by SB220025 reduces protein phosphatase
activity, which leads to increased JNK activity observed in
the present study. Interestingly, we found that JNK inhib-
itor SP600125 reversed the SB220025 stimulated increase
in JNK activity, NO production and iNOS expression, sug-
gesting that increased iNOS expression by SB220025
results from increased JNK activity. In addition, cyclohex-
imide, a known JNK activator, also increased LPS-induced
iNOS mRNA expression in a similar manner as SB220025.
The stimulatory effect of cycloheximide on iNOS mRNA
expression was reversed by SP600125, suggesting that the
effect of cycloheximide is at least partially mediated
through increased JNK activity. Up-regulatory role for JNK
in iNOS expression has been previously shown in IL-
1+IFN-γ-stimulated human fetal astrocytes [9], in
LPS+IFN-γ-stimulated RAW264.7γ macrophages [15], IL-
1β-stimulated rat primary mesangial cells [8]and LPS-
stimulated J774.A1 macrophages [10].
Regulation of iNOS mRNA stability seems to be an impor-
tant mean to regulate iNOS expression. However, the
mechanisms regulating iNOS mRNA stability are poorly
known. HuR is a mRNA stabilizing factor, which has been
shown to bind an AU-rich sequence element in the 3'
untranslated region of human iNOS mRNA and to stabi-
lise iNOS mRNA [31]. Tristetraprolin seems to have a role
as a mRNA stabilizing factor for human iNOS [32] while
the KH-type splicing regulatory protein (KSRP) has been
identified as a destabilizing factor [33]. Heterogeneous
nuclear ribonucleoproteins I and L have been reported to
interact with murine iNOS mRNA [34]. In addition, dex-
amethasone [35], protein kinase Cδ [36] and β-adrenergic
stimulation [37] have been shown to regulate iNOS
mRNA stability. Recently, we have shown that JNK inhib-
itor SP600125 reduces iNOS mRNA stability [10]. In the
present study, treatment with SB220025 had no effect on
iNOS mRNA levels when measured 4 h after LPS stimula-
tion, whereas a two fold increase in mRNA levels was
observed 10 h after LPS. Furthermore, mRNA levels
decreased slower in SB220025 treated cells than in cells
treated with LPS alone. These results together suggest that
SB220025 increases iNOS mRNA expression by stabilis-
ing mRNA. Also actinomycin D seems to have a stabilising
effect on iNOS mRNA. Actinomycin D has previously
been reported to stabilise mRNAs of transferrin receptor
[38] and cyclooxygenase-2 [39] but the mechanisms are
not known in detail.
Conclusion
The present results show that inhibition of p38 MAPK
enhances JNK activity, which leads to stabilisation of
iNOS mRNA, and to increased iNOS expression and NO
production. p38 MAPK regulates activity of JNK pathway
and it is therefore important to consider whether results
Effect of SB220025 on JNK activationFigure 7
Effect of SB220025 on JNK activation. Cells were stimu-
lated with LPS and SB220025. Incubations were terminated 
after 1 h and parallel immunoblots were run from same cell 
lysates using antibodies against Thr183/Tyr185 phosphor-
ylated JNK (pp54 and pp46), total JNK (p54 and p46). Phos-
phorylated JNK values were normalised to total JNK values. 
The result is representative of three experiments with simi-
lar results.
Effect of SB220025 on JNK activationFigure 6
Effect of SB220025 on JNK activation. Cells were stimu-
lated with LPS 1 h before addition of SB220025. Incubations 
were terminated at the indicated time points and parallel 
immunoblots were run from same cell lysates using antibod-
ies against Thr183/Tyr185 phosphorylated JNK (pp54 and 
pp46), total JNK (p54 and p46). Phosphorylated JNK values 
were normalised to total JNK values. Results are expressed 
as mean ± S.E.M. (n = 3). *P < 0.05, ***P < 0.001 compared 
with cells treated with LPS only.Page 7 of 12
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Effect of SB220025 on JNK activityFigure 8
Effect of SB220025 on JNK activity. (A) Cells were stimulated with LPS 1 h before addition of SB220025. Incubations were 
terminated at the indicated time points and parallel immunoblots were run from same cell lysates using antibodies against 
Ser63 phosphorylated c-Jun (pc-Jun) and total c-Jun. Results are expressed as mean (n = 4). (B) Cells were stimulated with LPS 
1 h before addition of tested compounds. Incubations were terminated 2 h after LPS and parallel immunoblots were run from 
same cell lysates using antibodies against Ser63 phosphorylated c-Jun (pc-Jun) and total c-Jun. Phosphorylated c-Jun values were 
normalised to total c-Jun values. Results are expressed as mean ± S.E.M (n = 3), *P < 0.05 compared with cells treated with LPS 
only.
BMC Pharmacology 2006, 6:5 http://www.biomedcentral.com/1471-2210/6/5obtained by inhibiting p38 MAPK might result from
increased JNK activity rather than from reduced p38
MAPK activity directly. Finally, based on our results, it
seems that JNK is an important post-transcriptional regu-
lator of LPS-induced iNOS expression and NO produc-
tion.
Methods
Materials
Reagents were obtained as follows: anthra(1,9-cd)pyra-
zol-6(2H)-one (SP600125), 4-ethyl-2-(4-methoxyphe-
nyl)-5-(4-hydroxyphenyl)-5-(4pyridyl)-imidazole
(SB202474), 5-(2-amino-4-pyrimidinyl)-4-(4-fluorophe-
nyl)-1-(4-piperidinyl)-imidazole(SB220025) and 4-(4-
fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-
imidazole (SB203580) (Calbiochem), rabbit polyclonal
mouse iNOS, c-Jun, JNK1 and actin antibodies, goat pol-
yclonal p38β antibody, donkey anti-goat antibody and
goat anti-rabbit polyclonal antibody (Santa Cruz Biotech-
nology Inc.), rabbit polyclonal p38 MAPK, phospho-p38
MAPK (Thr180/Tyr182), p38α, phospho-SAPK/JNK
(Thr183/Tyr185) and phospho-c-Jun (Ser63) II antibod-
ies (Cell Signaling technology). All other reagents were
from Sigma.
Cell culture
J774.2 macrophages (The European Collection of Cell
Cultures) were cultured at 37°C, 5% CO2 atmosphere, in
Dulbecco's Modified Eagle's Medium with glutamax-I
(Cambrex Bioproducts) containing 10% of heat inacti-
vated foetal bovine serum, 100 U/ml penicillin, 100 µg/
ml streptomycin and 250 ng/ml amphotericin B (all from
Invitrogen). Cells were seeded on 24 well plates for nitrite
measurements and in 6 well plates for Western blot and
RT-PCR and grown for 48 h prior to experiments.
Nitrite assays
At indicated time points the culture medium was collected
for nitrite measurement, which was used as a measure of
NO production. Culture medium (100 µl) was incubated
with 100 µl of Griess reagent (0.1% napthalethylenedi-
amine dihydrochloride, 1% sulphanilamine, 2.5%
H3PO4) and the absorbance was measured at 540 nm.
Preparation of cell lysates
At indicated time points cells were rapidly washed with ice
cold PBS and solubilised in cold lysis buffer containing 10
mM Tris-base, 5 mM EDTA, 50 mM NaCl, 1% Triton-X-
100, 0.5 mM phenylmethylsulfonyl fluoride, 2 mM sodi-
umorthovanadate, 10 µg/ml leupeptin, 25 µg/ml apro-
tinin, 1.25 mM NaF, 1 mM sodiumpyrophosphate and 10
mM n-octyl-β-D-glucopyranoside. After incubation for 20
min on ice, lysates were centrifuged (14500 g, 15 min)
and supernatants were mixed 1:4 with SDS loading buffer
(62.5 mM Tris-HCl, pH 6.8, 10% glycerol, 2% SDS,
Effect of SP600125 on LPS and SB220025 stimulated NO production and iNOS mRNA expressionFigure 9
Effect of SP600125 on LPS and SB220025 stimulated 
NO production and iNOS mRNA expression. (A) Cells 
were stimulated with LPS 1 h before addition of tested com-
pounds. 24 h after addition of LPS the nitrite concentrations 
were measured as marker of NO production. Values are 
mean ± S.E.M. (n = 6). (B) Cells were stimulated with LPS 1 h 
before addition of tested compounds. Incubations were ter-
minated 10 h after LPS and extracted total RNA was sub-
jected to real time RT-PCR. iNOS mRNA levels were 
normalized against GAPDH. Values are mean ± S.E.M. (n = 
4). *P < 0.05, ***P < 0.001 compared with cells treated with 
LPS only.Page 9 of 12
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boiled for 5 min. Protein concentrations in the samples
were measured by the Coomassie blue method [40].
Western blotting
Protein (30 µg) was loaded on 10% SDS-polyacrylamide
electrophoresis gel and electrophoresed for 4 h at 100 V in
buffer containing 95 mM Tris-HCl, 960 mM glycine and
0.5% SDS. After electrophoresis the proteins were trans-
ferred to Hybond ECL™ nitrocellulose membrane (Amer-
sham) with semi-dry blotter at 2.5 mA/cm2 for 60 min.
After transfer the membrane was blocked in TBS/T (20
mM Tris-base pH 7.6, 150 mM NaCl, 0.1% Tween-20)
containing 5% bovine serum albumin for 1 h at room
temperature and incubated with primary antibody in the
blocking solution at 4°C overnight. Thereafter the mem-
brane was washed 4× with TBS/T for 5 min, incubated
with secondary antibody in the blocking solution for 0.5
h at room temperature and washed 4× with TBS/T for 5
min. Bound antibody was detected using SuperSignal®
West Pico chemiluminescent substrate (Pierce) and
FluorChem™ 8800 imaging system (Alpha Innotech). The
quantitation of chemiluminescent signal was carried out
with FluorChem™ software v. 3.1.
RNA extraction and real-time RT-PCR
At indicated time points cell monolayers were rapidly
washed with ice cold PBS and cells were homogenised
using QIAshredder™ (QIAGEN Inc.). RNA extraction was
carried out with RNeasy® kit for isolation of total RNA
(QIAGEN inc.). Total RNA (25 ng) was reverse transcribed
to cDNA using TaqMan Reverse Transcription reagents
and random hexamers (Applied Biosystems). Reverse
transcriptase (RT) reaction parameters were as follows:
incubation at 25°C for 10 min, RT at 48°C for 30 min and
RT inactivation at 95°C for 5 min. cDNA obtained from
the RT reaction (amount corresponding approximately 1
ng of total RNA) was subjected to PCR using TaqMan®
Universal PCR Master Mix and ABI PRISM® 7000
Sequence detection system (Applied Biosystems). GAPDH
and iNOS primer and probe sequences and concentra-
tions were optimised according to manufacturers guide-
lines in TaqMan® Universal PCR Master Mix Protocol Part
Number 4304449 Rev. C and were as follows: 5'-CCTGG-
TACGGGCATTGCT-3', 5'-GCTCATGCGGCCTCCTT-3'
(forward and reverse mouse iNOS primer respectively,
both 300 nM), 5'-CAGCAGCGGCTCCATGACTCCC-
3'(mouse iNOS probe 150 nM, containing 6-FAM as 5'-
reporter dye) and 5'-GCATGGCCTTCCGTGTTC-3', 5'-
GATGTCATCATACTTGGCAGGTTT-3' (forward and
reverse mouse glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) primer respectively, both 300 nM), 5'-
TCGTGGATCTGACGTGCCGCC-3'(mouse GAPDH
probe 150 nM, containing 6-FAM as 5'-reporter dye)
(Metabion). Primers and probes for p38α (product
Effect of cycloheximide (CHX) on LPS-induced JNK activa-tion and iNOS mRNA expressiFigure 10
Effect of cycloheximide (CHX) on LPS-induced JNK 
activation and iNOS mRNA expression. (A) Cells were 
stimulated with LPS 1 h before addition of different concen-
trations of CHX. Incubations were terminated 2 h after LPS 
and parallel immunoblots were run from same cell lysates 
using antibodies against Thr183/Tyr185 phosphorylated JNK 
(pp54 and pp46), total JNK (p54 and p46). The result is rep-
resentative of two experiments with similar results. (B) Cells 
were stimulated with LPS 1 h before addition of CHX. Incu-
bations were terminated at indicated time points and 
extracted total RNA was subjected to real time RT-PCR. 
iNOS mRNA levels were normalised against GAPDH. Values 
are mean ± S.E.M. (n = 3). (C) Cells were stimulated with 
LPS 1 h before addition of tested compounds. Incubations 
were terminated 10 h after LPS and extracted total RNA was 
subjected to real time RT-PCR. iNOS mRNA levels were 
normalized against GAPDH. Values are mean ± S.E.M. (n = 
3). ***P < 0.001.Page 10 of 12
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Mm00440955_m1) (Applied Biosystems) were used as
recommended by the manufacturer. PCR reaction param-
eters were as follows: incubation at 50°C for 2 min, incu-
bation at 95°C for 10 min and thereafter 40 cycles of
denaturation at 95°C for 15 sec and annealing and exten-
sion at 60°C for 1 min. Each sample was determined in
duplicate.
A standard curve method was used to determine the rela-
tive iNOS and GAPDH mRNA levels as described in
Applied Biosystems User Bulletin #2. In short, a standard
curve for each gene was created using mRNA isolated from
LPS-stimulated J774.2 macrophages. Isolated RNA was
reverse transcribed as described. Dilution series were
made from obtained cDNA ranging from 10 ng to 1 pg
and were subjected to real time PCR as described.
Obtained threshold cycle values were plotted against dilu-
tion factor to create a standard curve. Relative mRNA lev-
els in test samples were then calculated from the standard
curve.
Statistics
Results are expressed as mean ± standard error of mean
(S.E.M.). When indicated, statistical significance was cal-
culated by analysis of variances supported by Bonferroni
multiple comparisons test. Differences were considered
significant at P < 0.05.
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